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BACKGROUND: Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemo-
therapy regimen is unknown. METHODS: From August 1998 to June 2009, data from 1099 patients with CLM were
collected prospectively. We retrospectively analyzed outcomes of patients who underwent resection of CLM after
second-line (2 or more) chemotherapy regimens. RESULTS: Sixty patients underwent resection of CLM after 2 or
more chemotherapy regimens. Patients had advanced CLM (mean number of CLM  standard deviation, 4  3.5;
mean maximum size of CLM, 5  3.2 cm) and had received 17  8 cycles of preoperative chemotherapy. In 54 (90%)
patients, the switch from the first regimen to another regimen was motivated by tumor progression or suboptimal ra-
diographic response. All patients received irinotecan or oxaliplatin, and the majority (42/60 [70%]) received a mono-
clonal antibody (bevacizumab or cetuximab) as part of the last preoperative regimen. Postoperative morbidity and
mortality rates were 33% and 3%, respectively. At a median follow-up of 32 months, 1-year, 3-year, and 5-year overall
survival rates were 83%, 41%, and 22%, respectively. Median chemotherapy-free survival after resection or completion
of additional chemotherapy administered after resection was 9 months (95% confidence interval, 4-14 months). Syn-
chronous (vs metachronous) CLM and minor (vs major) pathologic response were independently associated with
worse survival. CONCLUSIONS: Resection of CLM after a second-line chemotherapy regimen was found to be safe
and was associated with a modest hope for definitive cure. This approach represents a viable option in patients with
advanced CLM. Cancer 2011;117:4484–92. VC 2011 American Cancer Society.
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Colorectal cancer is one of the leading causes of cancer death worldwide and was responsible for an estimated
49,920 deaths in 2009 in the United States.1 In most cases, death occurs at the end of the evolution of metastatic disease,
and in the majority of patients, the liver is the first site of metastasis. In patients with colorectal liver metastases (CLM),
liver resection is the only treatment associated with long-term survival. In patients with unresectable CLM, chemotherapy
is the only therapy with a proven survival benefit, and resection may be possible in case of good response to chemother-
apy.2 In patients with resectable CLM, preoperative systemic chemotherapy has been used as part of the treatment strategy
to decrease the risk of recurrence after resection.3 Disease progression during preoperative chemotherapy predicts poor
outcome after resection.4 For patients with advanced disease and progression during preoperative chemotherapy, a change
to an alternate chemotherapy regimen is usually recommended, and liver resection may be reconsidered if there is disease
response or stabilization in response to the alternative chemotherapy.5 However, objective response rates to second-line
preoperative chemotherapy are only 4%-28%, hence surgery is rarely an option after failure of first-line chemotherapy.6-10
Furthermore, the safety, efficacy, and outcome of hepatic surgery in patients who received multiple lines of chemotherapy
have been evaluated only in small series of patients who received cetuximab or intra-arterial hepatic artery chemotherapy
infusion as a ‘‘rescue’’ regimen.11-13
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In this study, we analyzed the feasibility and out-
comes of resection of CLM after a second-line chemother-
apy regimen. We aimed to determine the role of liver
surgery in patients with advanced metastatic disease who
received multiple lines of chemotherapy because of subop-
timal response or toxicity after first-line chemotherapy.
MATERIALS AND METHODS
Patient Population and Definitions
Between August 13, 1998, and June, 17, 2009, data from
1099 consecutive patients who underwent surgical resec-
tion for CLM at 1 institution were collected prospectively.
Inclusion criteria for this study were resection of CLM fol-
lowing second-line (2 or more) chemotherapy regimens
and at least 1 year of follow-up after surgery. The study
was approved by the institutional review board of The
University of Texas MD Anderson Cancer Center
(RCR01-116).
Preoperative Chemotherapy
At The University of TexasMDAnderson Cancer Center,
the institutional guidelines for patients with CLM include
preoperative chemotherapy in almost all patients.5 Excep-
tions to this practice are patients who develop CLM less
than 1 year after adjuvant chemotherapy for the primary
tumor and patients with small volume CLM at risk of dis-
appearing during chemotherapy and that cannot have
their position radiographically labeled by a fiducial
marker.14,15 In patients with initially resectable CLM,
preoperative short-course chemotherapy (8-12 weeks) is
used. Patients with advanced CLM initially unsuitable for
resection are seen by the surgeon prior to initiation of
chemotherapy to determine whether the patient may be a
surgical candidate with a chemosensitive tumor (radio-
graphic response to chemotherapy). In patients with ini-
tially unresectable disease, surgical resection is considered
as soon as the lesions become resectable.5 During treat-
ment, restaging is performed every 3 to 4 cycles on the ba-
sis of clinical assessment and imaging. For this study,
imaging studies were retrospectively reviewed for each
patient to measure response according to the Response
Evaluation Criteria in Solid Tumors (RECIST)16
(response defined as complete response, partial response,
stable, or progressive disease) and morphologic criteria17
(response defined as none, incomplete, or optimal
response). Second-line chemotherapy was defined as any
change in chemotherapy regimen administered for CLM
except for the discontinuation of bevacizumab 6-8 weeks
before surgery. Adjuvant chemotherapy administered for
the primary tumor was not considered first-line chemo-
therapy for CLM except in patients with CLM detected at
the same time as the primary tumor (synchronous CLM)
and patients who developed CLM during adjuvant chem-
otherapy for the primary tumor. Reasons for receiving sec-
ond-line chemotherapy were classified into the following
categories: (1) progression during first-line chemotherapy,
(2) advanced metastases with suboptimal response to the
first-line chemotherapy regimen, or (3) intolerable toxic-
ity of the first-line chemotherapy regimen. A suboptimal
response was defined as a response insufficient to allow
safe resection based on volumetric assessment.
Surgical Procedure, Postoperative
Complications, and Pathologic Findings
Liver resections were performed only with curative
intent—that is, only if it was believed that a complete
tumor resection could be achieved. During laparotomy,
the peritoneal cavity was inspected to rule out extrahepatic
spread of disease. Hepatic palpation and intraoperative
ultrasonography were performed in all cases to better
define the location of the CLM in the liver and their rela-
tionship to portal pedicles and hepatic veins. Major hepa-
tectomy was defined as hepatic resection including 3 or
more contiguous liver segments. Radiofrequency ablation
was used in combination with liver resection and only for
small tumors in selected patients when a complete resec-
tion with staged resections and portal vein embolization
were not otherwise possible. Data on postoperative mor-
bidity and 90-day mortality were collected prospectively.
The severity of postoperative complications was graded
using the classification of Dindo et al.18 Complete patho-
logic response was defined as 0% of tumor cells viable,
major pathologic response as 1%-49% of tumor cells via-
ble, and minor pathologic response as 50% or more of tu-
mor cells viable.19 Changes of the nontumorous liver
parenchyma, including nonalcoholic fatty liver disease
(steatosis and steatohepatitis) and sinusoidal dilation,
were assessed semiquantitatively as described previ-
ously.20-22 Hepatic injury was defined as steatosis in more
than 30% of the hepatocytes and/or the presence of stea-
tohepatitis (Kleiner score >4) and/or moderate or severe
sinusoidal dilation.
Long-Term Outcome
The decision whether to deliver additional chemotherapy
after resection was made at the time of the follow-up post-
operative visit on an individualized basis, based on the
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presence of possible residual disease, response to preopera-
tive chemotherapy on imaging,16,17 tolerance and number
of cycles of preoperative chemotherapy, and pathologic
response. The policy was to avoid chemotherapy after resec-
tion when possible, because most patients who undergo
resection of CLM have already received prolonged chemo-
therapy. Patients were reassessed via physical examination,
carcinoembryonic antigen serum measurement, and multi-
phase (liver protocol) computed tomography examination
every 3-4 months after resection, and decisions about
further treatment were made according to the findings on
follow-up workup.
Statistical Analysis
Quantitative and qualitative variables were expressed as
mean standard deviation, median (range), and frequency.
Overall and disease-free survival were calculated using the
Kaplan-Meier method from the date of resection of CLM
and compared using a log-rank test. Chemotherapy-free sur-
vival was calculated from the date of resection of CLM in
patients who did not receive postoperative chemotherapy
and from the date of last dose of postoperative chemother-
apy in those who did receive postoperative chemotherapy.
For the detection of factors associated with survival
after resection of CLM following second-line chemother-
apy regimen, univariate analysis was used to examine the
relationship between overall survival and the following
clinicopathologic variables: rectal (vs other) location of
the primary tumor, presence of regional lymph node me-
tastases (v absence), synchronous (vs metachronous)
CLM, multiple (vs single) CLM (greater than 2), size of
CLM measured at the time of diagnosis (greater or less
than 5 cm), presence of extrahepatic disease, preoperative
serum CEA level >5 ng/dL, progression of disease during
first-line chemotherapy, intolerable toxic effects during
first-line chemotherapy, total number of cycles of chemo-
therapy, number of cycles of the last chemotherapy regi-
men, partial or stable disease after last chemotherapy
regimen according to RECIST criteria, morphologic
response after last chemotherapy regimen, occurrence of
major postoperative complications, pathologic response
(complete or major vs minor), and postoperative chemo-
therapy. All variables associated with survival with P < .2
in univariate proportional hazards model were subse-
quently entered into a Cox multivariate regression model
with backward elimination. P< .05 was considered statis-
tically significant. Comparisons between groups were ana-
lyzed via chi-squared or Fisher’s exact test for proportions,
Mann-Whitney U test for medians, and Student t test for
means, as appropriate. Statistical analysis was performed
using SPSS version 17.2 (SPSS, Chicago, IL).
RESULTS
Patient Characteristics
Among the 1099 patients who underwent resection of
CLM during the study period, 230 did not receive any pre-
operative chemotherapy, and 809 received only 1 line of
preoperative chemotherapy before surgery. The remaining
60 (5%) patients received 2 or more lines of preoperative
chemotherapy and were the subjects of our study. The
number of patients who underwent resection of CLM after
a second-line chemotherapy increased over time (Figure 1).
The patient characteristics are summarized in Table 1.
The majority (38/60 [63%]) of patients had synchronous
and multiple CLM. Twelve (20%) patients had at least 5
CLM, and 25 (42%) patients had CLMmeasuring at least
5 cm in diameter. The 13 patients who had metachronous
CLM had previously received adjuvant chemotherapy for
node-positive primary tumors (5-fluorouracil and levami-
sole in 8 patients, 5-fluorouracil and oxaliplatin in 5
patients). The median time between the last cycle of adju-
vant chemotherapy and the detection of CLM in these 13
patients was 28 months (range, 4-90 months). Fourteen
(23%) patients had extrahepatic disease, including 8
patients with resectable lung metastases, 5 patients with
portal node involvement, and 1 patient with pelvic local
recurrence of rectal cancer.
Preoperative Chemotherapy
Characteristics of preoperative chemotherapy are detailed
in Table 2. Most patients received oxaliplatin- or irinote-
can-based chemotherapy as first-line treatment. In most
Figure 1. The number of patients undergoing resection of
colorectal liver metastases after second-line chemotherapy
over time is shown.
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cases, the reason for a switch to a different chemotherapy
regimen was tumor progression or advanced disease with
insufficient response. In all patients, the last chemother-
apy regimen before resection included irinotecan or oxali-
platin, and in the majority, it was associated with either
cetuximab or bevacizumab. Most patients (39/60 [60%])
had prolonged chemotherapy (more than 6 months or
12 cycles). Twenty-two (37%) patients had objective
response (complete or partial tumor response) with the
last preoperative chemotherapy regimen according to the
RECIST criteria, and 16 (27%) patients had an optimal
morphologic response to the last preoperative chemother-
apy regimen.
Feasibility of Resection of CLM After
Second-Line Chemotherapy Regimen
Operative details and postoperative morbidity and mor-
tality are summarized in Table 1. The majority (40/60
[67%]) of patients underwent major liver resection. Two
(3%) patients died within 90 days postoperatively. One
patient developed postoperative bleeding after right hepa-
tectomy that necessitated reoperation; this patient subse-
quently developed irreversible hepatic failure. The other
patient had a bile leakage with multiple infectious compli-
cations after segmental resection and lymphadenectomy.
Ten (17%) patients developed major postoperative com-
plications necessitating a surgical, endoscopic, or radio-
logic procedure. On pathologic examination, 48 (80%)
patients had a complete resection, and 19 (32%) patients
had major or complete pathologic response to systemic
therapy. Upon histopathologic review of the nontumo-
rous liver, 15 (25%) patients had substantial hepatic
injury. Four patients had moderate or severe sinusoidal
injuries, 12 patients had steatosis >30%, and 4 patients
had steatohepatitis. Five (8%) patients had overlapping
injuries (steatosis>30% associated with steatohepatitis in
4 patients, steatosis>30% associated with moderate sinu-
soidal dilation in 1 patient).
Table 1. Clinicopathologic Characteristics, Operative Details,
and Postoperative Mortality and Morbidity
Characteristic Value
Age, y, meanSD 59  11
Sex, women:men 20:40
Rectal primary tumor 17 (28)
Positive lymph nodes 43 (72)
Synchronous liver metastases 47 (78)
No. of CLM, meanSD 4  3.5
Size of CLM at diagnosis, cm, meanSD 5  3.2
Bilateral liver metastases 24 (40)
Extrahepatic metastases 14 (23)
Preoperative plasma CEA level, ng/dL,
median (range)
7 (1-1192)
Preoperative portal vein embolization 6 (10)
Two-stage liver resection 5 (8)
Type of liver resection
Extended hepatectomy 15 (25)
Major hepatectomy 25 (42)
Minor liver resection 20 (33)
Resection combined with radiofrequency ablation 15 (25)
Estimated blood loss, mL, median (range) 337 (25-3100)
Transfusion of packed red blood cells 10 (17)
Positive surgical margins 12 (20)
Major or complete pathologic response 19 (32)
Death within 90 days after surgery 2 (3)
Postoperative morbidity 20 (33)
Major postoperative complication 10 (17)
SD indicates standard deviation; CLM, colorectal liver metastases; CEA,
carcinoembryonic antigen.
Data are presented as no. of patients (%) unless indicated otherwise.
Table 2. Preoperative Chemotherapy: Regimens, Numbers of
Cycles, and Response Rates
Characteristic Value
First chemotherapy regimen
5-FU-based 12 (20)
5-FU- and oxaliplatin-based 11 (18)
5-FU- and irinotecan-based 37 (62)
First chemotherapy regimen included bevacizumab 26 (43)
Indication for switch to second
chemotherapy regimen
Progression during first regimen 30 (50)
Advanced metastases with insufficient
response with or without toxicity
24 (40)
Intolerable toxicity 4 (6)
Empiric or unknown 2 (4)
No. of chemotherapy regimens received
2 57 (95)
>2 3 (5)
Last chemotherapy regimen
5- FU 1 irinotecan 14 (23)
5- FU 1 irinotecan 1 bevacizumab 17 (28)
5- FU 1 irinotecan 1 cetuximab 10 (17)
5- FU 1 oxaliplatin 4 (7)
5- FU 1 oxaliplatin 1 bevacizumab 12 (20)
5- FU 1 oxaliplatin 1 cetuximab 3 (5)
No. of cycles of last chemotherapy regimen,
meanSD
7.5  4.6
Total no. of cycles of preoperative
chemotherapy, meanSD
17  7.8
Radiographic response to last
chemotherapy regimen according to RECIST
Complete response 1 (2)
Partial response 21 (35)
Stable disease 22 (37)
Progressive disease 16 (27)
Optimal morphologic response to last chemotherapy regimen 16 (27)
5-FU indicates 5-fluorouracil; RECIST, Response Evaluation Criteria for
Solid Tumors; SD, standard deviation.
Data are presented as no. of patients (%) unless indicated otherwise.
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Long-Term Outcomes and Postoperative
Chemotherapy
After a median follow-up time of 32 months, 1-year, 3-year,
and 5-year overall survival rates were 83%, 41%, and 22%,
respectively, and 1-year, 3-year, and 5-year disease-free sur-
vival were 37%, 11%, and 11%, respectively (Figure 2).
Twenty-six (43%) patients received postoperative
chemotherapy. Forty-nine (81%) patients experienced re-
currence, and palliative chemotherapy was restarted in all
of them. Among these patients, 8 underwent surgery
(resection of lung metastases in 5 patients; repeat liver
resection in 2 patients; resection of local recurrence of
rectal cancer in 1 patient). Median chemotherapy-free sur-
vival time was 9.2 months (95% confidence interval, 4-14
months) after surgery or after the end of postoperative
chemotherapy (Figure 3). In the 34 patients who did not
receive postoperative chemotherapy, the median chemo-
therapy-free survival time was 12 months (95% confidence
interval, 6-18 months). Eight patients were alive and free of
disease 12 months after resection (Figure 4).
Predictors of Survival After Resection of CLM
After Second-Line Chemotherapy Regimen
Results of univariate and multivariate analysis for factors
associated with survival after resection of CLM after second-
line chemotherapy regimen are summarized in Table 3.
Univariate analysis showed that synchronous CLM, mul-
tiple CLM, absence of radiographic response or stability
of CLM by RECIST, and minor pathologic response were
associated with worse survival. On multivariate analysis,
only synchronous CLM and minor pathologic response
were independent factors of worse survival (Figure 5).
The 5-year survival rate was 10% in patients with both
factors, compared with 32% in patients with neither fac-
tor (P< .001).
DISCUSSION
Our study shows that hepatectomy for CLM after a sec-
ond-line chemotherapy regimen is feasible and associated
with a modest survival benefit in patients who present
with advanced CLM and have a suboptimal response to
systemic therapy. Although oncologic outcomes seen in
this series are not as good as previously reported after
resection of CLM after first-line chemotherapy, resection
of CLM after second-line chemotherapy regimen can be
associated with prolonged survival and a chemotherapy-
free interval and therefore represents a reasonable alterna-
tive in patients with advanced CLM.
To our knowledge, this is the largest series evaluat-
ing outcome of patients undergoing resection of CLM
after second-line chemotherapy regimen. We found
1-year and 3-year overall survival rates of 83% and 41%,
respectively, and 1-year and 3-year disease-free survival
rates of 37% and 11%, respectively. The 1-year overall
survival rate reported in this study compares favorably to
the 1-year survival rates of 28%-40% reported previously
in small series of patients treated with cetuximab or intra-
arterial hepatic artery chemotherapy infusion as second-
line therapy.11,13,23 This approach was associated with a
median chemotherapy-free interval of 9 months after liver
resection or after completion of additional chemotherapy
Figure 2. Overall and disease-free survival are shown. Figure 3. Chemotherapy-free survivals in patients who
received postoperative chemotherapy after resection of colo-
rectal liver metastases are shown. Chemotherapy-free survival
was calculated from the end of postoperative chemotherapy.
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administered after resection.We believe this represents an al-
ternative to maintenance chemotherapy in patients with
advanced disease in addition to modest possible survival
benefit.
Over the past decade, the oncosurgical strategy of
combining effective preoperative chemotherapy with an
aggressive surgical approach has received wide acceptance
for the treatment of CLM.2,3,19 In addition to lowering
recurrence rates after resection,3 preoperative chemother-
apy guides the treatment strategy, because tumor response
to preoperative chemotherapy represents a powerful prog-
nostic factor in patients undergoing resection.17,19 Tumor
progression during chemotherapy is considered a contra-
indication to resection of CLM by most oncologic teams.4
In patients who experience disease progression or develop
severe toxic effects during first-line chemotherapy, a sec-
ond-line regimen is usually introduced. Although this
approach has been shown to improve survival, reported
radiographic response rates after second-line chemother-
apy are only 4%-28%.6-10 Our finding of a 37% objective
radiographic response rate is consistent with rates reported
by others, illustrating the difficulty in obtaining a tumor
response with second-line chemotherapy. The extent of
the disease probably contributes to the 20% positive mar-
gins after resection in our population. However, this rate
remains acceptable with regard to previously reported
data in patients with advanced colorectal liver metastases
that can be up to 46%.24 Recently, yttrium 90 micro-
sphere hepatic artery radioembolization has been pro-
posed as an alternative to second-line chemotherapy as it
has been shown to improve survival compared to intrave-
nous fluorouracil in patients with unresectable CLM
refractory to therapy.25 However, with yttrium 90 radio-
embolization, the radiographic tumor response rate rarely
Figure 4. Contrast-enhanced computed tomography images of a 52-year-old man with diffuse multiple bilateral synchronous
colorectal liver metastases are shown. The images depict scans taken (A) at diagnosis, (B) after 4 cycles of FOLFOX and bevaci-
zumab, (C) after 6 cycles of FOLFIRI and bevacizumab followed by first stage resection of left liver metastases, and (D) after
second-stage right hepatectomy resection of liver metastases. Indication for second-line chemotherapy was advanced disease
with suboptimal response to therapy. The patient was alive and free of disease at last follow-up, 3 years after resection.
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exceeds 10%, and the median survival rarely exceeds
1 year.
The majority of patients in our series had disease
progression or a suboptimal response following first-line
chemotherapy. Interestingly, patients with progression
during first-line systemic therapy did not appear to have a
worse outcome than patients who were switched to a sec-
ond regimen because of inadequate response or toxic
effects. We identified synchronous metastases and patho-
logic response as prognostic factors in our patients and
found that the combination of these 2 factors adversely
affected survival (10% 5-year overall survival rate when
the 2 factors were present). The low rate of major or com-
plete pathologic response (32%) in this study compared
with data reported previously using modern first-line
chemotherapy (45%-58%) probably reflects unfavorable
tumor biology. Although the type of regimen, the dura-
tion of chemotherapy, and the use of a monoclonal anti-
body in first-line or last chemotherapy regimen was not
associated with prognosis, we believe that the administra-
tion of a monoclonal antibody (e.g., bevacizumab or
cetuximab) as second-line therapy when it was not
given as first-line therapy may be an option, because it is
associated with improved radiographic response rate or
survival in patients with advanced metastatic colorectal
cancer.11,19,26,27 Other recommendations to optimize
treatment strategy in these patients receiving second-line
chemotherapy for CLMmight focus on the timing of sur-
gery that should be proposed as soon as the disease is
resectable.
This study has some limitations. Study inclusion
was not based on the extent of the disease, because the def-
inition of resectability is often controversial,27 but on
treatment with second-line preoperative chemotherapy
regimens and subsequent liver resection with curative
intention. Not all patients received the same chemother-
apy regimens before surgery, and we did not analyze
patients with advanced CLM who received second-line
chemotherapy regimen and did not undergo resection. It
was a retrospective review of data acquired prospectively
and thus suffers from the limitations of retrospective
studies, including potential selection bias. However, we
believe that a phase 2 or 3 trial would be impractical to
address this question. The comparison with a nonre-
sected group was not performed, because resectable
CLM remain a surgical indication, and progression dur-
ing chemotherapy a relative contraindication to resec-
tion. It was not possible to select a population of patients
receiving chemotherapy only with comparable disease
extent.
In conclusion, this study showed that resection of
CLM following second-line chemotherapy regimen is fea-
sible and may be associated with a modest survival benefit.
Given the lack of highly effective treatment options for
Table 3. Univariate and Multivariate Analysis of Predictors of Survival
Predictor Univariate
Analysis
Multivariate
Analysisa
P P HR (95% CI)
Rectal primary tumor .26
Positive lymph nodes .98
Synchronous liver metastases .02 .003 4.5 (1.7-12)
Multiple CLM .02 .2
Maximum size of CLM 5 cm .6
Extrahepatic disease .28
CEA level >5 ng/dL .47
Progression during first chemotherapy regimen .28
Toxic effects during first chemotherapy regimen .82
Six or more cycles of second-line chemotherapy regimen .64
Sixteen or more cycles of total chemotherapy .16 .06
Radiographic response or stability after last
chemotherapy regimen
.01 .4
Morphologic response .25
Major postoperative complication .08 .1
Positive surgical margins .29
Minor pathologic response .05 .006 3.4 (1.4-8.2)
Postoperative chemotherapy .77
HR indicates hazard ratio; CI, confidence interval; CLM, colorectal liver metastases; CEA, carcinoembryonic antigen.
a Cox regression multivariate analysis included all variables with P<.2 on univariate analysis.
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patients with liver only metastatic disease with suboptimal
response to initial chemotherapy, we consider liver resec-
tion for selected patients following second-line therapy an
appropriate alternative. Not all patients receiving sec-
ond-line chemotherapy for advanced CLM can benefit
from resection, however; in the future, refinements in
the assessment of tumor response should help to select
surgical candidates in this challenging therapeutic
setting.17,28,29
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